Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Sep 14;107(11):djv248.
doi: 10.1093/jnci/djv248. Print 2015 Nov.

Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial

Carmen J Allegra  1 , Greg Yothers  2 , Michael J O'Connell  2 , Robert W Beart  2 , Timothy F Wozniak  2 , Henry C Pitot  2 , Anthony F Shields  2 , Jerome C Landry  2 , David P Ryan  2 , Amit Arora  2 , Lisa S Evans  2 , Nathan Bahary  2 , Gamini Soori  2 , Janice F Eakle  2 , John M Robertson  2 , Dennis F Moore Jr  2 , Michael R Mullane  2 , Benjamin T Marchello  2 , Patrick J Ward  2 , Saima Sharif  2 , Mark S Roh  2 , Norman Wolmark  2
Affiliations
Clinical Trial

Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial

Carmen J Allegra et al. J Natl Cancer Inst. .

Erratum in

Abstract

Background: National Surgical Adjuvant Breast and Bowel Project R-04 was designed to determine whether the oral fluoropyrimidine capecitabine could be substituted for continuous infusion 5-FU in the curative setting of stage II/III rectal cancer during neoadjuvant radiation therapy and whether the addition of oxaliplatin could further enhance the activity of fluoropyrimidine-sensitized radiation.

Methods: Patients with clinical stage II or III rectal cancer undergoing preoperative radiation were randomly assigned to one of four chemotherapy regimens in a 2x2 design: CVI 5-FU or oral capecitabine with or without oxaliplatin. The primary endpoint was local-regional tumor control. Time-to-event endpoint distributions were estimated using the Kaplan-Meier method. Hazard ratios were estimated from Cox proportional hazard models. All statistical tests were two-sided.

Results: Among 1608 randomized patients there were no statistically significant differences between regimens using 5-FU vs capecitabine in three-year local-regional tumor event rates (11.2% vs 11.8%), 5-year DFS (66.4% vs 67.7%), or 5-year OS (79.9% vs 80.8%); or for oxaliplatin vs no oxaliplatin for the three endpoints of local-regional events, DFS, and OS (11.2% vs 12.1%, 69.2% vs 64.2%, and 81.3% vs 79.0%). The addition of oxaliplatin was associated with statistically significantly more overall and grade 3-4 diarrhea (P < .0001). Three-year rates of local-regional recurrence among patients who underwent R0 resection ranged from 3.1 to 5.1% depending on the study arm.

Conclusions: Continuous infusion 5-FU produced outcomes for local-regional control, DFS, and OS similar to those obtained with oral capecitabine combined with radiation. This study establishes capecitabine as a standard of care in the pre-operative rectal setting. Oxaliplatin did not improve the local-regional failure rate, DFS, or OS for any patient risk group but did add considerable toxicity.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
CONSORT diagram: National Surgical Adjuvant Breast and Bowel Project protocol R-04. *All patients were assigned radiation therapy. †Includes pre- and post-amendment patients. ‡Post-amendment patients. FU = 5-fluorouracil; CAPE = capecitabine; OX = oxaliplatin.
Figure 2.
Figure 2.
Three-year event rate for patients treated with either continuous infusion 5-FU or capecitabine with or without oxaliplatin for (A) local-regional recurrence for all patients and (B) local-regional recurrence rates for only those patients achieving an R0 resection in National Surgical Adjuvant Breast and Bowel Project R-04. Note: No significant fluoropyrimidine by oxaliplatin interaction. L/R = local-regional.
Figure 3.
Figure 3.
Kaplan-Meier plots of local-regional recurrence for patients treated with (A) either continuous infusion 5-FU or capecitabine (B) with or without oxaliplatin in National Surgical Adjuvant Breast and Bowel Project R-04. L/R = local-regional.
Figure 4.
Figure 4.
Five-year event rates for (A) disease-free survival and (B) overall survival for patients treated with either continuous infusion 5-FU or capecitabine with or without oxaliplatin in National Surgical Adjuvant Breast and Bowel Project R-04. Note: No significant fluoropyrimidine-by-oxaliplatin interaction.
Figure 5.
Figure 5.
Kaplan-Meier plots of overall survival for patients treated with (A) either continuous infusion 5-FU or capecitabine (B) with or without oxaliplatin in National Surgical Adjuvant Breast and Bowel Project R-04.
See this image and copyright information in PMC

Comment in

  • Curing more colorectal cancer.
    Mallath MK, Chawla T. Mallath MK, et al. Natl Med J India. 2016 May-Jun;29(3):155-157. Natl Med J India. 2016. PMID: 27808066 No abstract available.

References

    1. Siegel R, Ma J, Zou Z, et al. Cancer Statistics, 2014. CA Cancer J Clin. 2014;64 (5):9–29. - PubMed
    1. O’Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994;331 (8):502–507. - PubMed
    1. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19 (21):4097–4106. - PubMed
    1. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19 (8):2282–2292. - PubMed
    1. Glen H, Cassidy J. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial. Expert Rev Anticancer Ther. 2008;8 (4):547–551. - PubMed

Publication types

MeSH terms